PT-00114 is under clinical development by Protagenic Therapeutics and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PT-00114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-00114 overview
PT-00114 (TCAP-1) is under development for the treatment of mood disorders, substance abuse and addiction, opioid addiction and other neurodegenerative disorders including post-traumatic stress disorder (PTSD), treatment resistant depression, generalized anxiety disorder. It is a synthetic form of the natural peptide sequence TCAP-1. It acts by targeting corticotropin-releasing hormone (CRH). It is developed based on peptide technology. It was also under development for the treatment of spinal cord injuries, ischemia and trauma. It is administered by subcutaneous route.
Protagenic Therapeutics overview
Protagenic Therapeutics operates as a biotechnology company. The Company focuses on the discovery and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The company is headquartered in the United States.
For a complete picture of PT-00114’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
